Table 2.
Medication use and duration
| Variable | All patients (n = 2407) | W-ES (n = 1995) | W-Met (n = 358) | M-ES (n = 42) | M-Met (n = 12) |
|---|---|---|---|---|---|
| Type of endocrine therapy (%) | |||||
| Tamoxifen* | 1277 (53.1) | 1033 (51.8) | 194 (54.2) | 38 (90.5) | 12 (100.0) |
| Tamoxifen-only | 578 (24.0) | 514 (25.8) | 23 (6.4) | 35 (83.3) | 6 (50.0) |
| Tamoxifen + AI* | 640 (26.6) | 471 (23.6) | 160 (44.7) | 3 (7.1) | 6 (50.0) |
| Raloxifene | 14 (0.6) | 11 (0.6) | 3 (0.8) | 0 | 0 |
| Any type of AI | 1747 (72.6) | 1422 (71.3) | 312 (87.2) | 7 (16.7) | 6 (50.0) |
| Anastrozole* | 1057 (43.9) | 906 (45.4) | 142 (39.7) | 5 (11.9) | 4 (25.0) |
| Exemestane* | 488 (20.3) | 388 (19.4) | 99 (27.7) | 1 (2.4) | 0 |
| Letrozole* | 858 (35.7) | 635 (31.8) | 217 (60.6) | 1 (2.4) | 5 (41.7) |
| AI-only | 949 (39.4) | 855 (42.9) | 90 (25.1) | 4 (9.5) | 0 |
| Fulvestrant | 127 (5.3) | 118 (5.9) | 7 (2.0) | 0 | 2 (16.7) |
| Leuprolide | 281 (11.7) | 208 (10.4) | 72 (20.1) | 0 | 1 (8.3) |
| Current ET use (%) | |||||
| < 5 years | 1464 (60.8) | 1277 (64.0) | 160 (44.7) | 21 (50.0) | 6 (50.0) |
| 5 years | 92 (3.8) | 74 (3.7) | 16 (4.5) | 2 (4.8) | 0 |
| 5 to 10 years | 282 (11.7) | 186 (9.3) | 85 (23.7) | 9 (21.4) | 2 (16.7) |
| > 10 years | 49 (2.0) | 21 (1.1) | 27 (7.5) | 1 (2.4) | 0 |
| I do not remember | 1 (0.04) | 1 (0.05) | 0 | 0 | 0 |
| Prior ET use (%) | |||||
| < 5 years | 287 (11.9) | 248 (12.4) | 31 (8.7) | 4 (9.5) | 4 (25.0) |
| 5 years | 118 (4.9) | 103 (5.1) | 11 (3.1) | 4 (9.5) | 0 |
| 5 to 10 years | 93 (3.9) | 72 (3.6) | 21 (5.9) | 0 | 0 |
| > 10 years | 21 (0.9) | 13 (0.6) | 7 (2.0) | 1 (2.4) | 0 |
AI aromatase inhibitor, ET endocrine therapy
*Multiple selections permitted
W-ES women, early stage
W-Met women, metastatic
M-ES men, early stage
M-Met men, metastatic